-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
PTACH
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/848354-66-5.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 848354-66-5 |
| Description | PTACH is a SAHA-based novel inhibitor of histone deacetylase (HDAC). It exerts potent growth inhibition against various human cancer cells, with EC50 values ranging from 1.1 to 9.1 μM. It shows strong activity in cancer cell growth inhibition assay. It inhibits various cancer cells with EC50 of 2.3, 9.1, 3.0, 2.6, 1.1, 4.5, 2.4, 5.0, and 4.5 μM for MDA-MB-231 breast cancer, SNB-78 central nervous system, HCT116 colon cancer, NCI-H226 lung cancer. It could inhibit the cell growth of a variety of lymphoid malignant cells through apoptosis induction, more effectively than SAHA. It upregulated anti-oxidant molecules including peroxiredoxin 1 and 2 and glutathione S-transferase at the protein level. It exhibits cytotoxicity by sustaining ROS at the higher level greater than SAHA. |
Product Information
| Synonyms | NCH-51; NCH 51; NCH51. PTACH;Cpd 51;S-(7-Oxo-7-((4-phenylthiazol-2-yl)amino)heptyl) 2-methylpropanethioate;S-[6-(4-Phenyl-2-thiazolylcarbamoyl)hexyl] thioisobutyrate;2-Methylpropanethioicacid S-[7-oxo-7-[(4-phenyl-2-thiazolyl)amino]heptyl]ester |
| IUPAC Name | S-[7-oxo-7-[(4-phenyl-1,3-thiazol-2-yl)amino]heptyl] 2-methylpropanethioate |
| Molecular Weight | 390.56 |
| Molecular Formula | C20H26N2O2S2 |
| Canonical SMILES | CC(C)C(=O)SCCCCCCC(=O)NC1=NC(=CS1)C2=CC=CC=C2 |
| InChI | InChI=1S/C20H26N2O2S2/c1-15(2)19(24)25-13-9-4-3-8-12-18(23)22-20-21-17(14-26-20)16-10-6-5-7-11-16/h5-7,10-11,14-15H,3-4,8-9,12-13H2,1-2H3,(H,21,22,23) |
| InChIKey | MDYDGUOQFUQOGE-UHFFFAOYSA-N |
| Melting Point | 127-128 °C | Condition: Solv: hexane (110-54-3); ethyl acetate (141-78-6) |
| Purity | >98% |
| Density | 1.181±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr |
| Solubility | DMSO:26mg/mL |
| Appearance | Solid powder |
| Application | PTACH exerts potent growth inhibition against various human cancer cells. It could inhibit the cell growth of a variety of lymphoid malignant cells through apoptosis induction. |
| Shelf Life | 2 month in rt, long time |
| Storage | 2-8°C |
| Complexity | 440 |
| Exact Mass | 390.14357042 |
| Index Of Refraction | 1.588 |
| In Vitro | PTACH (compound 51) treatment elevates the levels of acetylated histone H4 and p21WAF1/CIP1 in a dose-dependent manner. In cancer cell growth inhibition assay, PTACH (compound 51) shows strong activity. PTACH inhibits various cancer cells with EC50 values of 2.3 μM, 9.1 μM, 3.0 μM, 2.6 μM, 1.1 μM, 4.5 μM, 2.4 μM, 5.0 μM, and 4.5 μM for MDA-MB-231, SNB-78, HCT116, NCI-H226, LOX-IMVI, SK-OV-3, RXF-631L, St-4, and DU-145 cells, respectively. PTACH (NCH-51) augments the HIV-1 production in latently infected OM10.1 cells and such reactivation is associated with a loss of HDAC1 occupancy and subsequent hyperacetylation of histones in nuc-1 at the HIV-1 promoter. |
| PSA | 112.60000 |
| Target | HDAC; HIV |
| XLogP3-AA | 5.1 |
